The U.S. is canceling 22 BARDA-backed mRNA vaccine projects worth $500 mn, citing limited efficacy against respiratory viruses. Funding will shift to broader vaccine platforms. Moderna, Pfizer, and Sanofi drew trader attention, while sentiment turned bearish on AstraZeneca. MRNA is down 34.6% YTD; AZN is up 13.1%.